Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC Study: Olverembatinib, Blinatumomab, and Chidamide in Ph+ ALL
NCT06220487Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of olverembatinib, blinatumomab, tucidinostat in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Nanfang Hospital, Southern Medical University. Started Feb 2024; status: recruiting.
02
Drugs
olverembatinibblinatumomabtucidinostat
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT06220487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06220487.